Develops an investigational medicine for people with Wilson disease and radiopharmaceuticals for imaging and treating advanced cancers.
10-K for FY2025, filed Mar 27, 2026Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we,” “us,” and “our” and similar terms mean Monopar Therapeutics Inc. and its…View ↗
ALXN1840 (tiomolybdate choline) is an investigational once-daily, orally-administered drug candidate in development for the treatment of…View ↗
MNPR-101 is our proprietary humanized monoclonal antibody that we are developing for advanced solid tumors expressing uPAR. This novel…View ↗
Wilson disease treatment
The older report described a pipeline focused on cancer patients; the latest also includes development of a treatment for Wilson disease.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 27, 2026We are a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve quality…View ↗
Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we,” “us,” and “our” and similar terms mean Monopar Therapeutics Inc. and its…View ↗
Competes with Novartis, Bayer, Bristol Myers Squibb, Eli Lilly and, Actinium Pharmaceuticals, Johnson & Johnson, Telix Pharmaceuticals, Lantheus Holdings, AstraZeneca, Genentech, and CuraSight
10-K for FY2025, filed Mar 27, 2026Our MNPR-101 radiopharmaceutical program, including MNPR-101-Zr for imaging and MNPR-101-Lu and MNPR-101-Ac for therapy, is susceptible to…View ↗
Loading...